FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328129315> ?p ?o ?g. }

• W4328129315 endingPage "1883" @default.
• W4328129315 startingPage "1883" @default.
• W4328129315 abstract "Acute myelogenous leukemia (AML), the most prevalent acute and aggressive leukemia diagnosed in adults, often recurs as a difficult-to-treat, chemotherapy-resistant disease. Because chemotherapy resistance is a major obstacle to successful treatment, novel therapeutic intervention is needed. Upregulated ceramide clearance via accelerated hydrolysis and glycosylation has been shown to be an element in chemotherapy-resistant AML, a problem considering the crucial role ceramide plays in eliciting apoptosis. Herein we employed agents that block ceramide clearance to determine if such a reset would be of therapeutic benefit. SACLAC was utilized to limit ceramide hydrolysis, and D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-threo-PDMP) was used to block the glycosylation route. The SACLAC D-threo-PDMP inhibitor combination was synergistically cytotoxic in drug-resistant, P-glycoprotein-expressing (P-gp) AML but not in wt, P-gp-poor cells. Interestingly, P-gp antagonists that can limit ceramide glycosylation via depression of glucosylceramide transit also synergized with SACLAC, suggesting a paradoxical role for P-gp in the implementation of cell death. Mechanistically, cell death was accompanied by a complete drop in ceramide glycosylation, concomitant, striking increases in all molecular species of ceramide, diminished sphingosine 1-phosphate levels, resounding declines in mitochondrial respiratory kinetics, altered Akt, pGSK-3β, and Mcl-1 expression, and caspase activation. Although ceramide was generated in wt cells upon inhibitor exposure, mitochondrial respiration was not corrupted, suggestive of mitochondrial vulnerability in the drug-resistant phenotype, a potential therapeutic avenue. The inhibitor regimen showed efficacy in an in vivo model and in primary AML cells from patients. These results support the implementation of SL enzyme targeting to limit ceramide clearance as a therapeutic strategy in chemotherapy-resistant AML, inclusive of a novel indication for the use of P-gp antagonists." @default.
• W4328129315 created "2023-03-22" @default.
• W4328129315 creator A5002551163 @default.
• W4328129315 creator A5004302802 @default.
• W4328129315 creator A5004416971 @default.
• W4328129315 creator A5009408265 @default.
• W4328129315 creator A5016927543 @default.
• W4328129315 creator A5031335801 @default.
• W4328129315 creator A5031949915 @default.
• W4328129315 creator A5032107158 @default.
• W4328129315 creator A5041413158 @default.
• W4328129315 creator A5045331066 @default.
• W4328129315 creator A5047779719 @default.
• W4328129315 creator A5050154369 @default.
• W4328129315 creator A5055915620 @default.
• W4328129315 creator A5059706312 @default.
• W4328129315 creator A5071665510 @default.
• W4328129315 creator A5072643224 @default.
• W4328129315 creator A5075451106 @default.
• W4328129315 creator A5087128517 @default.
• W4328129315 creator A5089743794 @default.
• W4328129315 date "2023-03-21" @default.
• W4328129315 modified "2023-10-17" @default.
• W4328129315 title "Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia" @default.
• W4328129315 cites W1446970532 @default.
• W4328129315 cites W1872694920 @default.
• W4328129315 cites W1924762808 @default.
• W4328129315 cites W19618507 @default.
• W4328129315 cites W1981134294 @default.
• W4328129315 cites W1989482880 @default.
• W4328129315 cites W1997333990 @default.
• W4328129315 cites W1999160838 @default.
• W4328129315 cites W2006383153 @default.
• W4328129315 cites W2010336934 @default.
• W4328129315 cites W2017903224 @default.
• W4328129315 cites W2027151723 @default.
• W4328129315 cites W2028917256 @default.
• W4328129315 cites W2034081600 @default.
• W4328129315 cites W2048217586 @default.
• W4328129315 cites W2052575378 @default.
• W4328129315 cites W2069412624 @default.
• W4328129315 cites W2086125907 @default.
• W4328129315 cites W2090980124 @default.
• W4328129315 cites W2119468178 @default.
• W4328129315 cites W2128818493 @default.
• W4328129315 cites W2131888987 @default.
• W4328129315 cites W2135234617 @default.
• W4328129315 cites W2140079442 @default.
• W4328129315 cites W2141347249 @default.
• W4328129315 cites W2142009430 @default.
• W4328129315 cites W2143447170 @default.
• W4328129315 cites W2153332232 @default.
• W4328129315 cites W2172708546 @default.
• W4328129315 cites W2258932259 @default.
• W4328129315 cites W2276565531 @default.
• W4328129315 cites W2319085548 @default.
• W4328129315 cites W2345775535 @default.
• W4328129315 cites W2346843844 @default.
• W4328129315 cites W2518609640 @default.
• W4328129315 cites W2548144489 @default.
• W4328129315 cites W2584413057 @default.
• W4328129315 cites W2587246974 @default.
• W4328129315 cites W2608864912 @default.
• W4328129315 cites W2794088760 @default.
• W4328129315 cites W2806788650 @default.
• W4328129315 cites W2893964012 @default.
• W4328129315 cites W2895964723 @default.
• W4328129315 cites W2910786346 @default.
• W4328129315 cites W2942194156 @default.
• W4328129315 cites W2943458460 @default.
• W4328129315 cites W2966531802 @default.
• W4328129315 cites W2989775874 @default.
• W4328129315 cites W3006985196 @default.
• W4328129315 cites W3080263813 @default.
• W4328129315 cites W3092093589 @default.
• W4328129315 cites W3093139465 @default.
• W4328129315 cites W3106505937 @default.
• W4328129315 cites W3106920023 @default.
• W4328129315 cites W3164507051 @default.
• W4328129315 cites W3202054026 @default.
• W4328129315 cites W4226070825 @default.
• W4328129315 cites W587019821 @default.
• W4328129315 cites W2916141019 @default.
• W4328129315 doi "https://doi.org/10.3390/cancers15061883" @default.
• W4328129315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36980769" @default.
• W4328129315 hasPublicationYear "2023" @default.
• W4328129315 type Work @default.
• W4328129315 citedByCount "0" @default.
• W4328129315 crossrefType "journal-article" @default.
• W4328129315 hasAuthorship W4328129315A5002551163 @default.
• W4328129315 hasAuthorship W4328129315A5004302802 @default.
• W4328129315 hasAuthorship W4328129315A5004416971 @default.
• W4328129315 hasAuthorship W4328129315A5009408265 @default.
• W4328129315 hasAuthorship W4328129315A5016927543 @default.
• W4328129315 hasAuthorship W4328129315A5031335801 @default.
• W4328129315 hasAuthorship W4328129315A5031949915 @default.
• W4328129315 hasAuthorship W4328129315A5032107158 @default.
• W4328129315 hasAuthorship W4328129315A5041413158 @default.

• next